【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

當多數生技公司仍在燒錢求生，什麼訊號代表它已經跨過「死亡谷」？
當一筆 3 億營收出現，這只是收入，還是技術被市場驗證的關鍵里程碑？
當負債一年下降 84%，這背後是財務操作，還是戰略轉型的開始？
本集我們邀請到漢康生技財務長——曾木增（Alan），從資本市場視角，深度拆解漢康如何在高強度研發壓力下，打造可持續的現金流與成長引擎。

精彩內容：

• 從燒錢到回血的轉折點：為什麼授權金不只是收入，而是生技公司從「講故事」走向「現金流驗證」的關鍵分水嶺？

• 資本結構的戰略重整：當負債大幅下降、股權結構優化，如何直接影響估值、募資能力與法人進場意願？

• 臨床里程碑導向的資金配置：漢康如何不是平均燒錢，而是精準押注 HCB101 與 HCB301，讓每一筆研發支出都對應價值提升？

• 從募資到選資金的權力轉移：當公司不再缺錢，如何提升談判力，甚至改寫未來授權條件？

• 平台型公司的現金流想像：當 FBDB 平台持續產出新 Pipeline，為什麼這代表未來授權收入有機會「持續複利」？

【About This Episode】
When most biotech companies are still burning cash to survive, what signals that one has crossed the “valley of death”?
When a company reports NTD 300 million in revenue, is it just income—or proof that its technology has been validated by the market?
When liabilities drop by 84% in a single year, is it financial engineering—or the beginning of a strategic transformation?
In this episode, we invite HanchorBio’s CFO, Alan Tseng, to break down how the company is building a sustainable cash flow engine while navigating the intense demands of biotech R&D.

【Key Takeaways】
The Turning Point from Burn to Cash Recovery:Why is licensing revenue more than just income—and instead a critical inflection point that marks the shift from storytelling to real cash flow validation?
Strategic Capital Structure Optimization:How do lower liabilities and a cleaner balance sheet directly impact valuation, fundraising power, and institutional investor confidence?
Milestone-Driven Capital Allocation:Instead of burning cash evenly, how does Hanchor prioritize key assets like HCB101 and HCB301 to ensure every dollar spent translates into measurable value?
From Raising Capital to Choosing Capital:What changes when a company no longer needs money—and how does that shift negotiation power with investors and global pharma partners?
The Compounding Potential of a Platform Model:As the FBDB platform continuously generates new pipelines, how could this translate into scalable and recurring licensing opportunities?


漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。